BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.29. Operator: Thank you for standing by. My name ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...